| Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study | BMJ, The | 2016 | 280 |
| Stroke prevention in atrial fibrillation | Lancet, The | 2016 | 228 |
| Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis | Thrombosis and Haemostasis | 2016 | 190 |
| Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial | Lancet, The | 2016 | 173 |
| EACVI/EHRA Expert Consensus Document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation | European Heart Journal Cardiovascular Imaging | 2016 | 170 |
| Effects of Quercetin on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials | Journal of the American Heart Association | 2016 | 141 |
| Validation of digital pathology imaging for primary histopathological diagnosis | Histopathology | 2016 | 132 |
| Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms | Atherosclerosis | 2016 | 117 |
| Atrial fibrillation | Nature Reviews Disease Primers | 2016 | 115 |
| The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials | Thrombosis and Haemostasis | 2016 | 110 |
| Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF) | American Heart Journal | 2016 | 95 |
| Causes of Death and Influencing Factors in Patients with Atrial Fibrillation | American Journal of Medicine | 2016 | 90 |
| Role and analysis of monocyte subsets in cardiovascular disease. Joint consensus document of the European Society of Cardiology (ESC) Working Groups "Atherosclerosis & Vascular Biology" and "Thrombosis" | Thrombosis and Haemostasis | 2016 | 86 |
| Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States | International Journal of Clinical Practice | 2016 | 85 |
| Use of Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation Who Have a History of Intracranial Hemorrhage | Circulation | 2016 | 83 |
| Atrial Fibrillation and Thromboembolism in Patients With Chronic Kidney Disease | Journal of the American College of Cardiology | 2016 | 80 |
| Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores | Journal of Thrombosis and Haemostasis | 2016 | 77 |
| Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin | American Journal of Medicine | 2016 | 75 |
| Acrylate and methacrylate contact allergy and allergic contact disease: a 13-year review | Contact Dermatitis | 2016 | 69 |
| Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: Temporal trends 2011-2015 in Denmark | Scientific Reports | 2016 | 68 |
| Clinical Characteristics and Outcomes in Extreme Elderly (Age ≥ 85 Years) Japanese Patients With Atrial Fibrillation: The Fushimi AF Registry | Chest | 2016 | 68 |
| Current Status and Time Trends of Oral Anticoagulation Use Among Chinese Patients With Nonvalvular Atrial Fibrillation: The Chinese Atrial Fibrillation Registry Study | Stroke | 2016 | 62 |
| Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups | International Journal of Cardiology | 2016 | 62 |
| Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting | Clinical Cardiology | 2016 | 58 |
| Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial | Clinical Research in Cardiology | 2016 | 58 |
